Ann Marie Bradley

Suggest Changes
Learn More
OBJECTIVES Taxanes have reported response rates of 20% to 40% in recurrent ovarian cancer (ROC) but are less well studied as a later-line treatment. We reviewed our experience with taxanes in ROC to(More)
  • 1